<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Alvotech — News on 6ix</title>
<link>https://6ix.com/company/alvotech</link>
<description>Latest news and press releases for Alvotech on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Fri, 24 Apr 2026 12:30:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/alvotech" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835458b78dffbe2df0e2990.webp</url>
<title>Alvotech</title>
<link>https://6ix.com/company/alvotech</link>
</image>
<item>
<title>Alvotech to Report Financial Results for the First Quarter of 2026</title>
<link>https://6ix.com/company/alvotech/news/alvotech-to-report-financial-results-for-the-first-quarter-of-2026</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-to-report-financial-results-for-the-first-quarter-of-2026</guid>
<pubDate>Fri, 24 Apr 2026 12:30:00 GMT</pubDate>
<description>REYKJAVIK, ICELAND (April 24, 2026) — Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it will release its first quarter 2026 financial results on Wednesday, May 6, 2026, after the U.S. market close. The Company will also host a webcast with a live Q&A on Thursday, May 7, 2026, at 08:00 EST (12:00 GMT, 13:00 BST, 14:00 CEST). To listen to the webca</description>
</item>
<item>
<title>Alvotech Publishes 2025 Annual Report</title>
<link>https://6ix.com/company/alvotech/news/alvotech-publishes-2025-annual-report</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-publishes-2025-annual-report</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has published its Annual Report for 2025. The report is available in the</description>
</item>
<item>
<title>Alvotech Files Annual Report with the SEC</title>
<link>https://6ix.com/company/alvotech/news/alvotech-files-annual-report-with-the-sec-1</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-files-annual-report-with-the-sec-1</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>REYKJAVIK, Iceland, March 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial</description>
</item>
<item>
<title>Alvotech files Annual Report with the SEC</title>
<link>https://6ix.com/company/alvotech/news/alvotech-files-annual-report-with-the-sec</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-files-annual-report-with-the-sec</guid>
<pubDate>Mon, 30 Mar 2026 04:00:00 GMT</pubDate>
<description>REYKJAVIK, ICELAND (March 30, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”) has filed its Annual Report 2025 on Form 20-F for the financial year 2025 with</description>
</item>
<item>
<title>Alvotech Q4 2025 and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/alvotech/news/alvotech-q4-2025-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-q4-2025-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>REYKJAVIK, Iceland, March 18, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB) Financial Highlights A supplemental</description>
</item>
<item>
<title>Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/alvotech/news/alvotech-to-report-fourth-quarter-and-full-year-2025-financial-results-10</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-to-report-fourth-quarter-and-full-year-2025-financial-results-10</guid>
<pubDate>Wed, 04 Mar 2026 05:00:00 GMT</pubDate>
<description>REYKJAVIK, ICELAND (March 4, 2026) — Alvotech (NASDAQ: ALVO) (the “Company”), a global biotechnology company specializing in the development and manufacture</description>
</item>
<item>
<title>Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®</title>
<link>https://6ix.com/company/alvotech/news/alvotech-announces-positive-top-line-results-pivotal-pharmacokinetic-study-proposed-0</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-announces-positive-top-line-results-pivotal-pharmacokinetic-study-proposed-0</guid>
<pubDate>Thu, 05 Feb 2026 05:00:00 GMT</pubDate>
<description>The study, which assessed the pharmacokinetics, safety, tolerability and immunogenicity of AVT80 compared to Entyvio® in healthy adult participants, met all</description>
</item>
<item>
<title>Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates</title>
<link>https://6ix.com/company/alvotech/news/alvotech-enters-supply-and-commercialization-agreements-canada-and-australia-new-0</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-enters-supply-and-commercialization-agreements-canada-and-australia-new-0</guid>
<pubDate>Mon, 02 Feb 2026 05:00:00 GMT</pubDate>
<description>REYKJAVIK, ICELAND (February 2, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar</description>
</item>
<item>
<title>Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg</title>
<link>https://6ix.com/company/alvotech/news/alvotech-secures-settlement-agreement-global-markets-its-biosimilar-eylear-2mg-2026-0</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-secures-settlement-agreement-global-markets-its-biosimilar-eylear-2mg-2026-0</guid>
<pubDate>Thu, 29 Jan 2026 05:00:00 GMT</pubDate>
<description>REYKJAVIK, ICELAND (January 29, 2026) — Alvotech (NASDAQ: ALVO), a global biotechnology company specializing in the development and manufacture of biosimilar</description>
</item>
<item>
<title>Correction: Transactions of Managers and Closely Associated Persons</title>
<link>https://6ix.com/company/alvotech/news/correction-transactions-managers-and-closely-associated-persons-2026-01-07</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/correction-transactions-managers-and-closely-associated-persons-2026-01-07</guid>
<pubDate>Wed, 07 Jan 2026 05:00:00 GMT</pubDate>
<description>Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely</description>
</item>
<item>
<title>Alvotech announces planned CEO succession and leadership transition</title>
<link>https://6ix.com/company/alvotech/news/alvotech-announces-planned-ceo-succession-121500507</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-announces-planned-ceo-succession-121500507</guid>
<pubDate>Tue, 06 Jan 2026 12:15:00 GMT</pubDate>
<description>Photo of Lisa Graver Lisa Graver, incoming CEO of Alvotech - Róbert Wessman to continue serving as Executive Chairman in full-time capacity - Lisa Graver...</description>
</item>
<item>
<title>Transactions of Managers and Closely Associated Persons</title>
<link>https://6ix.com/company/alvotech/news/transactions-managers-and-closely-associated-persons-2026-01-06-0</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/transactions-managers-and-closely-associated-persons-2026-01-06-0</guid>
<pubDate>Tue, 06 Jan 2026 05:00:00 GMT</pubDate>
<description>Attached is a copy of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely</description>
</item>
<item>
<title>Alvotech Secures Term Loan Facility of USD 100 Million</title>
<link>https://6ix.com/company/alvotech/news/alvotech-secures-term-loan-facility-usd-100-million-2025-12-31-0</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-secures-term-loan-facility-usd-100-million-2025-12-31-0</guid>
<pubDate>Wed, 31 Dec 2025 05:00:00 GMT</pubDate>
<description>USD 100 million senior term loan facility with a 2-year maturityStrengthens liquidity to support execution across Alvotech’s R&D pipeline and global product</description>
</item>
<item>
<title>Alvotech’s Financial Calendar for 2026</title>
<link>https://6ix.com/company/alvotech/news/alvotechs-financial-calendar-2026-2025-12-22</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotechs-financial-calendar-2026-2025-12-22</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>Alvotech (NASDAQ: ALVO, ALVO SDB) today publishes its financial calendar for 2026. Annual or interim results are released on the dates specified below, after</description>
</item>
<item>
<title>Alvotech announces European launch of first-in-market biosimilar to Simponi® (golimumab) globally by partner Advanz Pharma</title>
<link>https://6ix.com/company/alvotech/news/alvotech-announces-european-launch-first-market-biosimilar-simponir-golimumab-0</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-announces-european-launch-first-market-biosimilar-simponir-golimumab-0</guid>
<pubDate>Mon, 22 Dec 2025 05:00:00 GMT</pubDate>
<description>Introduction of AVT05 supported by NHS England tender award in the United Kingdom REYKJAVIK, ICELAND (December 22, 2025) — Alvotech (NASDAQ: ALVO), a global</description>
</item>
<item>
<title>Alvotech and Teva Secure U.S. Settlement Date for AVT06, a Proposed Biosimilar to Eylea®</title>
<link>https://6ix.com/company/alvotech/news/alvotech-and-teva-secure-us-settlement-date-avt06-proposed-biosimilar-eylear-2025-12</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-and-teva-secure-us-settlement-date-avt06-proposed-biosimilar-eylear-2025-12</guid>
<pubDate>Fri, 19 Dec 2025 05:00:00 GMT</pubDate>
<description>According to the settlement agreement, the proposed biosimilar to Eylea® (aflibercept) can be marketed in the U.S., if approved by the FDA, in the fourth</description>
</item>
<item>
<title>Alvotech Successfully Places USD 108 Million Senior Unsecured Convertible Bonds in a Significantly Oversubscribed Offering</title>
<link>https://6ix.com/company/alvotech/news/alvotech-successfully-places-usd-108-million-senior-unsecured-convertible-bonds</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-successfully-places-usd-108-million-senior-unsecured-convertible-bonds</guid>
<pubDate>Wed, 17 Dec 2025 05:00:00 GMT</pubDate>
<description>THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW</description>
</item>
<item>
<title>Alvotech Launches $100 Million Senior Unsecured Convertible Bond Offering to Continue Strong Investment in R&D, Support Manufacturing, Global Product Launches and Enhance Liquidity Position, reaffirms 2025 outlook and provides 2026 guidance</title>
<link>https://6ix.com/company/alvotech/news/alvotech-launches-100-million-senior-unsecured-convertible-bond-offering-continue</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-launches-100-million-senior-unsecured-convertible-bond-offering-continue</guid>
<pubDate>Tue, 16 Dec 2025 05:00:00 GMT</pubDate>
<description>THIS PRESS RELEASE MAY NOT BE DISTRIBUTED, RELEASED, OR PUBLISHED, DIRECTLY OR INDIRECTLY, IN OR INTO AUSTRALIA, BELARUS, CANADA, HONG KONG, JAPAN, NEW</description>
</item>
<item>
<title>Alvotech Announces Approval of AVT03, a Biosimilar to Prolia® and Xgeva® (denosumab) in the European Economic Area</title>
<link>https://6ix.com/company/alvotech/news/alvotech-announces-approval-avt03-biosimilar-proliar-and-xgevar-denosumab-european-0</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-announces-approval-avt03-biosimilar-proliar-and-xgevar-denosumab-european-0</guid>
<pubDate>Mon, 24 Nov 2025 05:00:00 GMT</pubDate>
<description>REYKJAVIK, ICELAND (November 25, 2025) — Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar</description>
</item>
<item>
<title>Alvotech and Advanz Pharma Receive Marketing Approval Across the European Economic Area for Gobivaz®, a First-in-Market Biosimilar to Simponi® (golimumab)</title>
<link>https://6ix.com/company/alvotech/news/alvotech-and-advanz-pharma-receive-marketing-approval-across-european-economic-area-0</link>
<guid isPermaLink="true">https://6ix.com/company/alvotech/news/alvotech-and-advanz-pharma-receive-marketing-approval-across-european-economic-area-0</guid>
<pubDate>Thu, 20 Nov 2025 05:00:00 GMT</pubDate>
<description>Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz</description>
</item>
</channel>
</rss>